Cormorant Asset Management PRAX Position
Active9-Fund ConvergenceCormorant Asset Management trimmed their position in Praxis Precision Medicines, Inc. (PRAX) in Q4 2025, holding $280.0M worth of shares across 950,000 shares.
The position was first reported in Q2 2023 and has been tracked across 11 quarterly 13F filings.
PRAX is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for 1mg elsunersen in 77 days (Jun 30, 2026), making the timing of Cormorant's position particularly relevant.
Short interest stands at 13.5% of float with 9.3 days to cover, indicating significant bearish positioning against Cormorant's long thesis.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Full company profile →Short Interest
13.5%
9.3 days to cover
Cormorant Asset Management PRAX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 950,000 | -50,000 | $280.0M |
| Q3 2025 | Decreased | 1,000,000 | -625,000 | $53.0M |
| Q2 2025 | Decreased | 1,625,000 | -120,000 | $68.3M |
| Q1 2025 | Increased | 1,745,000 | +51,781 | $66.1M |
| Q4 2024 | Increased | 1,693,219 | +823,219 | $130.3M |
| Q3 2024 | Increased | 870,000 | +185,000 | $50.1M |
| Q2 2024 | Decreased | 685,000 | -625,000 | $28.3M |
| Q1 2024 | Increased | 1,310,000 | +676,655 | $79.9M |
| Q4 2023 | Decreased | 633,345 | -8,866,655 | $14.1M |
| Q3 2023 | Held | 9,500,000 | — | $16.2M |
| Q2 2023 | New | 9,500,000 | +9,500,000 | $10.9M |
Frequently Asked Questions
Does Cormorant Asset Management own PRAX?
Yes. As of Q4 2025, Cormorant Asset Management holds 950,000 shares of Praxis Precision Medicines, Inc. (PRAX) valued at $280.0M. This data comes from their SEC 13F filing.
How many hedge funds own PRAX?
9 specialist biotech hedge funds currently hold PRAX, including Perceptive Advisors, Baker Bros. Advisors, Driehaus Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy PRAX?
Cormorant Asset Management's position in PRAX was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's PRAX position increasing or decreasing?
Cormorant Asset Management trimmed their PRAX position in the most recent quarter, reducing by 50,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PRAXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →